拓扑替康
米托蒽醌
拓扑异构酶
Abcg2型
新生霉素
阿霉素
癌症研究
药理学
细胞培养
细胞毒性
喜树碱
化学
依托泊苷
流出
医学
多重耐药
化疗
柔红霉素
蒽环类
作者
Chih-Hsin Yang,Yao-Chang Chen,Min-Liang Kuo
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2003-05-01
卷期号:23: 2519-2523
被引量:32
摘要
Background: Novohiocin was shown to sensitize cancer cells to etoposide and alkylating agents. Human breast carcinoma cells exposed to topotecan (MCF7/TPT300 cells) developed resistance to both mitoxantrone and topotecan. An ATP-binding cassette family protein BCRP/MXR/ABCP was overexpressed in MCF7/TPT300 cells. In addition, topotecan efflux was markedly enhanced in the resistant cells. To investigate the possibility that novohiocin may enhance cytotoxicity in BCRP/MXR/ABCP overexpressing cells, we exposed MCF7/TPT300 cells to novohiocin. Materials and Methods: Cytotoxicity tests of topotecan and mitoxantrone, as well as topotecan accumulation tests, were performed with or without novobiocin in MCF7/TPT300 cells. Results: Novobiocin enhances topotecan and mitoxantrone toxicity in MCF7/TPT300 cells at a clinically relevant concentration. Novobiocin enhanced cellular accumulation of topotecan and inhibited topotecan efflux in MCF7/TPT300 cells. Conclusion: Novohiocin may enhance topotecan and mitoxantrone toxicity in topotecan-resistant breast carcinoma cells. Novohiocin may be useful to reverse topotecan or mitoxantrone resistance in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI